The global gene therapy market for Severe Combined Immunodeficiency (SCID) is poised for significant growth, projected to reach $2 billion by 2034. Driven by advancements in gene therapy techniques, the market is witnessing an increase in collaborations and partnerships between pharmaceutical companies and research institutions. This article dives into the key trends shaping the market, highlighting successful treatments like Strimvelis and the potential of gene editing for SCID.